STERIS (NYSE:STE - Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of $2.12 per share for the quarter. STERIS has set its FY25 guidance at $9.05-$9.25 EPS and its FY 2025 guidance at 9.050-9.250 EPS.Persons interested in registering for the company's earnings conference call can do so using this link.
STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping analysts' consensus estimates of $1.98 by $0.16. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The firm had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same period last year, the company earned $2.00 earnings per share. The business's revenue for the quarter was down .4% on a year-over-year basis. On average, analysts expect STERIS to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.
STERIS Stock Performance
Shares of NYSE:STE traded up $0.52 during midday trading on Wednesday, reaching $224.39. 434,571 shares of the company traded hands, compared to its average volume of 474,129. The firm's fifty day moving average price is $234.38 and its two-hundred day moving average price is $226.73. The firm has a market capitalization of $22.13 billion, a price-to-earnings ratio of 55.55 and a beta of 0.84. The company has a quick ratio of 1.49, a current ratio of 2.33 and a debt-to-equity ratio of 0.35. STERIS has a 12 month low of $195.47 and a 12 month high of $248.24.
Insider Buying and Selling
In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the transaction, the chief financial officer now directly owns 42,930 shares of the company's stock, valued at approximately $10,603,710. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of the company's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the sale, the chief financial officer now directly owns 42,930 shares in the company, valued at $10,603,710. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Christopher S. Holland sold 473 shares of STERIS stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $239.68, for a total value of $113,368.64. Following the completion of the transaction, the director now owns 582 shares in the company, valued at approximately $139,493.76. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
STE has been the subject of a number of analyst reports. Needham & Company LLC restated a "hold" rating on shares of STERIS in a research report on Thursday, August 8th. Stephens reaffirmed an "overweight" rating and issued a $260.00 price target on shares of STERIS in a report on Wednesday, August 7th. JMP Securities restated a "market outperform" rating and set a $265.00 target price on shares of STERIS in a research report on Wednesday, August 7th. Piper Sandler upgraded STERIS from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $230.00 to $260.00 in a research report on Thursday, October 24th. Finally, KeyCorp upped their price objective on shares of STERIS from $255.00 to $265.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 3rd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $253.00.
Read Our Latest Stock Analysis on STERIS
About STERIS
(
Get Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
See Also
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
